

Croissy Beaubourg, December 19th, 2023

Object: Merger of Theradiag with Biosynex

Dear Partner,

You are among our partners, and we thank you for this cooperation.

As you already know, Biosynex and Theradiag have built a stronger link during the past months. On December 15th, 2023, both shareholders' general assemblies gathered and approved the merge between Biosynex and Theradiag.

This merger represents a major step in the development of Theradiag and Biosynex. It allows the creation of a stronger group that will bring you an improved service with broader product portfolio, ordering process, logistics and after-sales services.

We are looking forward to continuing our collaboration with you within the Biosynex group. Our teams remain at your disposal to ensure the best transition and to answer any question you may have at <u>informations@biosynex.com</u>

In any case, we will come back to you early in 2024 to communicate the updated information for your systems.

Best regards,

Simon Davière

EMEA Diagnostics Director







BIOSYNEX THERADIAG

14 rue Ambroise Croizal 77183 Croissy Beaubourg• France Tel. : 01 64 62 10 12 • Fax : 01 64 62 09 66

BIOSYNEX S.A. 22 Boulevard Sébastien Brant 67400 Illkirch-Graffenstaden • France Tel. : 03 88 78 80 88 • Fax : 03 88 78 76 78

SA au capital de 1 028 148 € - RCS : 481 075 703 - APE 2120Z - lieu de juridiction : Strasbourg